Proteins constitute the largest segment of biologic drugs – monoclonal antibodies in particular are often very sensitive. The inner coating of SCHOTT’s Type I plus® keeps container-drug interaction to a minimum, while SCHOTT EVERIC™ pure vials deliver unmatched drug stability for low-filling volumes, minimizing the risk of delamination. For customers who want to reduce their costs during lyophilization due to fogging, we offer SCHOTT TopLyo®.Read More
Since most vaccines are produced on a mass scale and may also require transportation to some of the world’s most remote areas, stable storage is vital, along with a seamless fill + finish process. SCHOTT TopLyo® can reduce rejections due to zero fogging during lyophilization, while EVERIC™ offers a high level of chemical resistance, as well as optimized container strength and an outer coating for smooth processing.
Gene therapy is one of the fastest growing areas of biologics, where genetically modified cells or vectors are introduced to the patient in order to influence the body’s response to threats or replace defective genes. Since these therapies often target a very small patient population, drug batches are highly valuable, so the SCHOTT adaptiQ® pre-sterilized platform offers increased flexibility for filling with no glass-to-glass contact.
Sr. Global Product Manager